Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle by Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna Rosenheck, Sivasankar Putta, Alec Trub, John Bisi, Jay Strum, Patrick Roberts, Seth M. Rubin, Costakis Frangou, Karen McLean, Agnieszka K. Witkiewicz, Erik S. Knudsen

“…The co-expression of these genes occurs in breast cancer patients highlighting their clinical significance as predictive biomarkers for CDK2-targeted therapies. …”
Get full text

Patients’ and plastic surgeons’ experiences with an online patient decision aid for breast reconstruction: considerations for nationwide implementation by Jacqueline A. ter Stege, Ellen G. Engelhardt, Leonie A.E. Woerdeman, Hester S.A. Oldenburg, Jacobien M. Kieffer, Daniela E.E. Hahn, Frederieke H. van Duijnhoven, Martine A. van Huizum, Regina The, Klemens Karssen, Marianne Kuenen, Miranda A. Gerritsma, Quinten (PQ) Ruhe, Irene S. Krabbe-Timmerman, Martijne van’t Riet, Nikola (AN) Kimmings, Eveline M.L. Corten, Kerry A. Sherman, Arjen J. Witkamp, Eveline M.A. Bleiker

“…Abstract Background Women diagnosed with breast cancer undergoing a mastectomy often have the option to undergo breast reconstruction (BR). …”
Get full text

Desmoid-type fibromatosis of the breast: a case report and literature review by Zijun Zhao, Qingyao Shang, Chenxuan Yang, Jiaxiang Liu, Shanqing Liu, Xiaoqian Li, Xiyu Kang, Jiaxian Yue, Xin Wang, Xiang Wang

“…It has a high recurrence rate, although distal metastasis is uncommon. It resembles breast cancer clinically, and histological pathology is the only approach to a confirmed diagnosis. …”
Get full text

Personalized treatment strategies for breast adenoid cystic carcinoma: A machine learning approach by Sakhr Alshwayyat, Mahmoud Bashar Abu Al Hawa, Mustafa Alshwayyat, Tala Abdulsalam Alshwayyat, Siya sawan, Ghaith Heilat, Hanan M. Hammouri, Sara Mheid, Batool Al Shweiat, Hamdah Hanifa

“…Background: Breast adenoid cystic carcinoma (BACC) is a rare subtype of breast cancer that accounts for less than 0.1 % of all cases. …”
Get full text

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report by Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan, Brigitte Rack, Uwe Gerstenmaier, Ambros J. Beer, Regine Mayer-Steinacker, Wolfgang Thaiss, Thomas F. E. Barth, Thomas Seufferlein, Nadine T. Gaisa, Stephan Stilgenbauer, Wolfgang Janni, Reiner Siebert, Hartmut Döhner, Verena I. Gaidzik

“…Case presentation We present the case of a woman with breast cancer and subsequent osteosarcoma, both treated with surgery and chemotherapy. …”
Get full text

Pathological and radiological assessment of benign breast lesions with BIRADS IVc/V subtypes. should we repeat the biopsy? by Wesam Rjoop, Anwar Rjoop, Alia Almohtaseb, Lama Bataineh, Zeina Nser Joubi, Maha Gharaibeh, Abdalrahman Al-Qwabah, Yousef Alasheh, Ismail Matalka

“…Abstract Background Timely diagnosis is a crucial factor in decreasing the death rate of patients with breast cancer. BI-RADS categories IVc and V indicate a strong suspicion of cancer. …”
Get full text

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells agains... by Weiting Liao, Ge Gao, Xia He, Pei Shu, Qizhi Ma, Benxia Zhang, Diyuan Qin, Yongsheng Wang

“…Next, we explored the possible combination of S1PR3 antagonist with murine EpCAM-targeted CAR-T cells in immunocompetent mouse models of breast cancer and colon cancer. The results indicated that the S1PR3 antagonist could significantly enhance the efficacy of murine EpCAM CAR-T cells in vitro and in vivo. …”
Get full text

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…In vivo antitumor activity was investigated in a triple-negative breast cancer (TNBC) model and primary melanoma tumor model in immunocompromised mice.Results Monoclonal antibody 2D2 identified from phage-displayed library specifically bound to NY-ESO-1157-165 in the context of human leukocyte antigen HLA-A*02:01 but not to non-A2 or NY-ESO-1 negative cells. …”
Get full text

Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries by Anna Johansson, Anna Skog, Tom Børge Johannesen, Tor Åge Myklebust, Simon M. Kønig, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Marnar Fríðheim Kristiansen, David Pettersson, Eva María Gudmundsdóttir, Nanna Margrét Kristinsdóttir, Helgi Birgisson, Sandra Irenaeus, Johan Ahlgren, Mats Lambe, Elli Hirvonen, Janne Pitkäniemi, Giske Ursin

“…Incidence rates also declined in the second pandemic wave (Q1 2021), ranging from –8.6% [–10.2%; –6.9%] (Sweden) to –2.3% [–4.6%; 0.1%] (Norway), and in Sweden also by –3.1% [–4.8%; –1.3%] in the third pandemic wave (Q4 2021). Stage I breast cancer incidence declined during 2020 in Denmark/Norway/Sweden, with some catch-up in stage II incidence in 2021. …”
Get full text

Factors associated with breast lymphedema after adjuvant radiation therapy in women undergoing breast conservation therapy by Summer Sami Yono, Cara Cannella, Madeleine Gonte, Sanjay Rama, Simeng Zhu, Jenna Luker, Maristella S. Evangelista, Jessica Bensenhaver, Eleanor M. Walker, Dunya Atisha

“…Methods: A retrospective cohort study of patients with early-stage breast cancer who underwent breast-conserving surgery (lumpectomy) followed by RT between January 1, 2014 and July 31, 2019 at a single institution. …”
Get full text

Personalized medicine: An alternative for cancer treatment by Devendra Singh, Vinay Kumar Dhiman, Minakshi Pandey, Vivek Kumar Dhiman, Avinash Sharma, Himanshu Pandey, Sunil Kumar Verma, Rajeev Pandey

“…Prostate, colon, lung, and breast cancers are the most common types of cancer. In India, it is estimated that there will be around 2.7 million cancer patients by 2020. …”
Get full text